Loading...
Status of post-treatment measurable residual disease (MRD) in peripheral blood and bone marrow correlates with clinical outcome in B-cell lymphomas. To prospectively assess the predictive value of this biomarker in mantle cell lymphoma (MCL), investigators in Italy conducted a multicenter, randomized, phase 3 trial involving 300 previously untreated MCL patients who received induction rituximab plus chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT). Patients were then randomized to maintenance lenalidomide or observation for 24 months.
Peripheral blood and bone marrow samples were obtained at multiple predetermined time points during each phase of treatment and every 6 months during and after com…